Illumina, Inc. (NASDAQ:ILMN) Shares Bought by CCLA Investment Management

CCLA Investment Management lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 20.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 535,050 shares of the life sciences company’s stock after buying an additional 91,122 shares during the quarter. CCLA Investment Management’s holdings in Illumina were worth $71,493,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Green Alpha Advisors LLC increased its holdings in Illumina by 82.9% during the 4th quarter. Green Alpha Advisors LLC now owns 4,693 shares of the life sciences company’s stock valued at $627,000 after acquiring an additional 2,127 shares in the last quarter. ORG Wealth Partners LLC grew its position in shares of Illumina by 68.1% in the fourth quarter. ORG Wealth Partners LLC now owns 3,030 shares of the life sciences company’s stock valued at $405,000 after purchasing an additional 1,227 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in shares of Illumina by 2.2% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 18,170 shares of the life sciences company’s stock worth $2,369,000 after purchasing an additional 394 shares in the last quarter. Weybosset Research & Management LLC raised its position in shares of Illumina by 14.3% during the 4th quarter. Weybosset Research & Management LLC now owns 20,638 shares of the life sciences company’s stock worth $2,758,000 after purchasing an additional 2,586 shares during the last quarter. Finally, Partnership Wealth Management LLC lifted its stake in Illumina by 17.0% in the 4th quarter. Partnership Wealth Management LLC now owns 8,095 shares of the life sciences company’s stock valued at $1,082,000 after buying an additional 1,175 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Stock Performance

Illumina stock opened at $136.48 on Wednesday. The company has a market cap of $21.65 billion, a price-to-earnings ratio of -13.70 and a beta of 1.11. Illumina, Inc. has a 12 month low of $100.08 and a 12 month high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The stock’s 50-day moving average is $140.55 and its 200-day moving average is $133.10.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. During the same period in the previous year, the company posted $0.33 earnings per share. Illumina’s revenue was down 3.5% compared to the same quarter last year. Equities analysts anticipate that Illumina, Inc. will post 4.11 earnings per share for the current year.

Analyst Upgrades and Downgrades

ILMN has been the subject of several recent research reports. Leerink Partners raised their price target on Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. UBS Group lifted their price objective on Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Canaccord Genuity Group boosted their target price on shares of Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research note on Tuesday, November 5th. Royal Bank of Canada raised their price target on shares of Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. Finally, HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price target for the company in a report on Thursday, October 17th. Eight research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $165.63.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.